Wall Street analyst estimates for Veracyte, Inc. (VCYT): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-03 | $0.43 | ||
| 2026-07-30 | $0.54 | $0.41 | +31.6% |
| 2026-05-05 | $0.52 | $0.34 | +52.9% |
| 2026-02-25 | $0.53 | $0.41 | +29.8% |
| 2025-11-04 | $0.51 | $0.32 | +59.4% |
| 2025-08-06 | $0.44 | $0.31 | +41.9% |
| 2025-05-07 | $0.31 | $0.12 | +151.8% |
| 2025-02-24 | $0.07 | $0.10 | -30.0% |
Valuation Ratios
| P/E Ratio | 32.72 |
| Price / Book | 2.63 |
| EV / EBITDA | 26.17 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.1M | $72.0M | $92.0M | $120.4M | $117.5M | $219.5M | $296.5M | $361.1M | $445.8M | $517.1M |
| Cost of Revenue | $25.5M | $28.2M | $33.1M | $36.5M | $41.5M | $74.4M | $101.6M | $112.9M | $147.6M | $157.1M |
| Gross Profit | $39.6M | $43.8M | $58.9M | $83.8M | $76.0M | $145.1M | $195.0M | $248.1M | $298.1M | $360.0M |
| Research & Development | $15.3M | $13.9M | $14.8M | $14.9M | $17.2M | $29.8M | $40.6M | $57.3M | $69.3M | $70.8M |
| Selling, General & Admin | $52.0M | $55.3M | $65.3M | $82.7M | $89.1M | $181.2M | $174.1M | $184.2M | $206.0M | $210.9M |
| Operating Expenses | $68.4M | $70.3M | $81.2M | $99.0M | $111.4M | $227.0M | $236.0M | $333.9M | $282.0M | $285.9M |
| Operating Income | -$28.8M | -$26.5M | -$22.2M | -$15.1M | -$35.4M | -$81.9M | -$41.1M | -$85.8M | $16.1M | $74.2M |
| EBITDA | -$25.1M | -$23.8M | -$17.1M | -$7.8M | -$26.7M | -$60.2M | -$7.0M | -$49.4M | $49.2M | $89.6M |
| Interest Expense | $2.8M | $4.9M | $2.0M | $677,000 | $229,000 | $241,000 | $198,000 | $15,000 | $2,000 | 0 |
| Pre-tax Income | -$31.4M | -$31.0M | -$23.0M | -$12.6M | -$34.9M | -$81.6M | -$36.4M | -$76.6M | $25.7M | $68.2M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | -$6.1M | $133,000 | -$2.2M | $1.6M | $1.8M |
| Net Income | -$31.4M | -$31.0M | -$23.0M | -$12.6M | -$34.9M | -$75.6M | -$36.6M | -$74.4M | $24.1M | $66.4M |
| EPS | $-1.09 | $-0.91 | $-0.62 | $-0.27 | $-0.66 | $-1.11 | $-0.51 | $-1.02 | $0.32 | $0.84 |
| EPS (Diluted) | $-1.09 | $-0.91 | $-0.62 | $-0.27 | $-0.66 | $-1.11 | $-0.51 | $-1.02 | $0.31 | $0.82 |
| Shares Outstanding (Diluted) | $28.8M | $33.9M | $37.0M | $46.1M | $53.2M | $67.9M | $71.5M | $72.6M | $78.2M | $80.6M |
Price
| Price | $47.67 |
| Market Cap | $3.8B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ADPT · IDYA · IRON · KNSA · LEGN
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of VCYT: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks